NCT01784536已完成1 期
Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Change in the phenotyping measures of each probe drug in the absence and presence of oritavancin
研究概览
简要总结
The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provides written informed consent before study initiation.
- •Healthy male or female adult between 18 and 45 years of age, inclusive.
- •Body mass index (BMI) between 18 and 32 kg/m^2, inclusive.
- •Nonsmoker for a 6-month period before Screening.
- •In good health based upon results of medical history, physical examination, no clinically significant 12-lead ECG results, and laboratory test results.
- •Agrees to avoid all medications (other than the study drugs) that may inhibit or induce hepatic microsomal enzymes during the study period, including prescription and nonprescription medications, vitamins, herbal supplements (including energy drinks), and nutraceuticals.
- •Female subject is surgically sterile, postmenopausal, or, if of childbearing potential, agrees to use an acceptable nonhormonal method of contraception during all study phases.
- •Agree to abstain from alcohol, caffeine-, and xanthine-containing products, all kind of energy drinks and the consumption of grapefruit juice and orange juice from 48 hours before study drug administration until completion of the follow-up visit.
排除标准
- •Has acute or chronic respiratory disease.
- •The use of nonprescription drugs during the 30-day period before screening.
- •The use of any prescription drugs during the 3-month period before.
- •Childbearing potential, a positive test result for urine or serum, human chorionic gonadotropin (hCG) at Screening.
- •Positive serology result for hepatitis B surface antigen, hepatitis C virus antibody, or has known hepatitis B or C infection at screening.
- •Positive serology result for human immunodeficiency virus (HIV) or has known immune deficiency disease at Screening.
- •Requires anticoagulant monitoring with an activated partial thromboplastin time.
- •Has an elevated international normalized ratio >1.
- •Surgical or medical condition that could interfere with the administration of the study drug.
- •Any condition that may affect drug absorption.
- •Has a known intolerance to benzodiazepines, the active and/or inactive ingredients in caffeine, warfarin, vitamin K, omeprazole, or dextromethorphan.
- •The use of any nicotine containing substance or nicotine replacement devices within 6 months before Screening.
- •Has received an immunization during the 2-week period before screening.
- •Has hemorrhagic tendencies or blood dyscrasias.
- •Has poor venous access as determined by the investigator.
- •Reports regular alcohol intake exceeding 1 drink/day within 1 month before screening.
- •A poor metabolizer (based on medical history, if known) of CYP2D6, CYP2C9, or CYP2C
- •Has participated in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days before enrollment.
- •Excluded for any of the previous criteria may not be rescreened for participation at any time.
研究组 & 干预措施
Oritavancin
Experimental
Single-Dose IV Oritavancin Diphosphate
干预措施: Single-Dose IV Oritavancin Diphosphate (Drug)
结局指标
主要结局
Change in the phenotyping measures of each probe drug in the absence and presence of oritavancin
时间窗: Day 1 through Day 5
次要结局
- Safety of probe drug administration and prolonged infusion of oritavancin as assessed by AEs/SAEs, clinical safety laboratory results, vital sign measurements, 12 lead ECG results, and physical examination findings(Day 1 through Day 28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy SubjectsHealthy VolunteersNCT02621385Vanda Pharmaceuticals24
已完成
1 期
Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, FluvoxamineHealthy VolunteersNCT01540500Vanda Pharmaceuticals24
已完成
1 期
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) PharmacokineticsNCT06689527Santhera Pharmaceuticals18
已完成
4 期
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)NeoplasmsNauseaVomitingNCT00684463Merck Sharp & Dohme LLC59
已完成
1 期
A Study to Assess the Effect of Rifampin on the Metabolism of NavitoclaxLymphoma, Including Chronic Lymphocytic LeukemiaSolid TumorsNCT01121133AbbVie12